AGEN Agenus Inc: רווח למניה בשנים עשר החודשים האחרונים

Agenus develops innovative antibodies to combat cancer, which opens prospects for lucrative licensing. However, FDA rejections and liquidity shortages have created serious financial risks. The company's expertise in immuno-oncology confirms its medical authority. The trailing 12-month earnings per share trend on the GURU.Markets chart shows that the metric is holding at 0.73.
פילוחים אנליטיים ודוחות נתונים של חברת Agenus, Inc. (AGEN)

This indicator measures the aggregate net income of Agenus (AGEN) over the last four quarters distributed per common share, allowing for an assessment of the actual efficiency of capital generation. By analyzing the rolling earnings per share (EPS) metric, an investor can gauge the financial stability of Agenus (AGEN) amid the automation of drug synthesis via AI and high clinical trial costs.